OccuLogix Rheo trial
This article was originally published in The Gray Sheet
Executive Summary
FDA approves an investigational device exemption for a 300-patient pivotal study of the firm's Rheo blood filtration system to treat the "dry" form of age-related macular degeneration, OccuLogix announces Jan. 29. Slated to begin this quarter, the multi-site, sham-controlled trial will evaluate vision improvement according to an acuity scale at one-year follow-up. The firm's previous trial for the device failed to meet its primary endpoint. Currently there is no FDA-approved treatment for dry AMD, which accounts for up to 90% of AMD patients, OccuLogix says...
You may also be interested in...
OccuLogix cuts back
OccuLogix fires seven members of its executive team in January following the indefinite suspension of clinical development for the RHEO blood filtration system to treat "dry" age-related macular degeneration. Also, CEO Elias Vamvakas and Chief Operating Officer Tom Reeves have agreed to take a 50% pay cut. The Toronto company announced plans for a 300-patient, sham-controlled pivotal trial of RHEO last February, but recently decided the project is not financially feasible following a review of the projected costs and development timeline (1"The Gray Sheet" Feb. 5, 2007, In Brief). The company also is exploring strategic alliances or selling all or part of the company. The firm sold its SOLX glaucoma business in December for $5 million plus future royalties. OccuLogix retains its San Diego-based OcuSense division, which plans to launch the TearLab diagnostic system in 2008. TearLab measures tear film osmolarity, a quantitative biomarker for dry eye
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.